Background: Our goal was to determine in healthy individuals and individuals with type 2 diabetes the impact of repeated episodes of hypoglycemia on the corrected QT (QTc) interval and the time course for QTc recovery. Further, since hypoglycemia increases aldosterone and patients with primary aldosteronism have prolonged QTc, we also determined whether mineralocorticoid receptor blockade prevents hypoglycemia-induced QTc alterations.
Methods: Twenty-seven healthy participants completed a double-blinded crossover trial contrasting 3 experimental conditions: 1) euglycemia, 2) hypoglycemia, and 3) hypoglycemia with mineralocorticoid receptor blockade pretreatment. Sixteen participants with type 2 diabetes completed 1 condition, hypoglycemia. Hyperinsulinemic clamps were performed to induce the hypoglycemic and euglycemic conditions. EKGs were performed before, during, and after the clamps.
Results: Healthy participants had a significant (P < 0.0001) prolongation of QTc during both the morning and afternoon hypoglycemic clamps as compared with euglycemic clamps (morning hypoglycemia vs euglycemia: 439.06 ± 41.18 ms vs 406.96 ± 26.16 ms; afternoon hypoglycemia vs euglycemia: 441.50 ± 34.36 ms vs 407.78 ± 19.18 ms). MR blockade did not alter the response to hypoglycemia. Participants with diabetes achieved a significant prolongation of QTc during the afternoon hypoglycemia only (afternoon hypoglycemia vs morning baseline: 461.96 ± 49.14 vs. 428.90 ± 28.54, P < 0.05). In both participant populations, QTc intervals were similar to baseline 90 minutes after return to euglycemia and the following day.
Conclusion: Hypoglycemia prolonged QTc in healthy participants and this was not altered by MR blockade. In individuals with type 2 diabetes, two hypoglycemic episodes were required to achieve prolongation. Reassuringly, in both study populations hypoglycemia-induced QTc prolongation resolved quickly with no apparent residual effects the next day.
Keywords: QT interval; Type 2 Diabetes; hypoglycemia.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. See the journal About page for additional terms.